Live Breaking News & Updates on வினோத் ராமச்சந்திரன்
Stay updated with breaking news from வினோத் ராமச்சந்திரன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Reddyâs files application for Reeqonus tablets to treat COVID-19 in Canada Dr. Reddyâs, alongside Global Response Aid and Appili Therapeutics, has filed an application on behalf of Reeqonus (favipiravir) tablets in Canada. âOur outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation, said Mitch Wilson, CEO of GRA. The filing is a testimony to our commitment of bringing a potential solution to COVID-19 for the Canadian population.â The companies have filed a motion for the tablets to be used for the acute treatment of mild to moderate COVID-19 in adult patients under Health Canadaâs Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. ....
Dr Reddy s Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients. The application has been filed under Health Canada s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy s said in a statement. In September, the interim order was signed by Canada s Minister of Health to create a new authorisation pathway that will help expedite the authorisation of drugs and vaccines for COVID-19. ....
Dr. Reddy's files application for Reeqonus tablets to treat mild COVID-19 in Canada drugstorenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drugstorenews.com Daily Mail and Mail on Sunday newspapers.
Posted on 10423 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. REEQONUS™ is also known as Avigan® (favipiravir) Tablets, developed by FUJIFILM Toyama Chemical Co., Ltd. ....
Updated: Share Article AAA Dr. Reddy’s Laboratories Canada Inc., on behalf of a consortium, has filed an application with Health Canada seeking authorisation for Reeqonus (favipiravir) tablets for the acute treatment of mild to moderate COVID-19 adult patients. “Dr. Reddy’s is working closely with Health Canada for an expedited review of the drug application as speed to market is essential”, VP and general manager Vinod Ramachandran said. “If approved, it will launch the product soon for COVID-19 patients in Canada,” he added. Dr. Reddy’s Canada has filed the application on behalf of the consortium comprising Dr. Reddy’s Laboratories, Appili Therapeutics and Global Response Aid FZCO (GRA) under Health Canada’s interim order “respecting the importation, sale and advertising of drugs for use in relation to COVID-19.” ....